June 26, 2022 11:22 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Ram Gopal Varma lands in fresh controversy over tweet on Droupadi Murmu | Counting underway for by-polls in 3 Lok Sabha, 7 Assembly seats | Indian skipper Rohit Sharma tests positive for Covid-19 | 'Supreme Court took away Constitutional right from Americans': Joe Biden on abortion ruling | Covid-19: Telangana records 493 new cases
Kolkata fights COVID-19: Narayan Memorial Hospital Behala successfully conducts ‘Antibody Cocktail Therapy’ on two of its patients Narayan Memorial Hospital

Kolkata fights COVID-19: Narayan Memorial Hospital Behala successfully conducts ‘Antibody Cocktail Therapy’ on two of its patients

India Blooms News Service | @indiablooms | 19 Jun 2021, 03:54 pm

Kolkata: Narayan Memorial Hospital on Saturday announced that they have successfully implemented ‘Antibody Cocktail Therapy’ on two of it's patients.

The patients are keeping well and are without any further complications.

Casiririvimab and Imdevimab are indicated for restricted emergency use for the treatment of mild to moderate Covid-19 in patients who are at high risk of severe COVID 19.

NMH said it is partnering  Cipla Limited in addressing unmet patient need and look toward leveraging this innovative treatment for the people of Kolkata.

Speaking on the occasion Ms. Suparna Sengupta, CEO, Narayan Memorial Hospital said, “We are now at per with other cities in India to provide broader, equitable access to this innovative treatment. We are thankful to Cipla in bringing it to Kolkata and Narayan Memorial Hospital, the youngest but dedicated Hospital towards serving patients in the most ablestmanner.“

She further added,  “We are optimistic that the availability of Antibody Cocktail (Casirivimab and Imdevimab) in India can help in minimizing hospitalisation, ease the burden on healthcare systems and play a key role in treatment of high risk patients before their condition worsens."

Dr. Subhrojyoti Bhowmick, Clinical Trial Expert said, “The antibody cocktail (Casirivimab and Imdevimab) is to be administered for the treatment of mild to moderate coronavirusdisease 2019 (COVID-19) in adults and pediatric patients (12 years of age or older, weighing at least 40 kg) who are confirmed to be infected with SARS-COV2 and who are at high risk of developing severe COVID-19 disease and do not require oxygen. It has been shown to help these high-risk patients before their condition worsens, reducing the risk of hospitalisation and fatality by 70% and shortening the duration of symptoms by four days.”